Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of VCD vs VTD induction, autologous stem cell transplantation, and bortezomib maintenance in newly diagnosed multiple myeloma
KCT0002959Phase 3Completed
- Sponsor
- Chong Kun Dang
- Start
- Oct 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in multiple myeloma (MM), sponsored by Chong Kun Dang. Started Oct 2018; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0002959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002959.